Title

An Assessment of the Real-World Data Platform TriNetX for Measuring the Association Between Group A Streptococcus and Neuropsychiatric Diagnoses

Authors

Shawn Gao, BS (sgao2@stanford.edu)

Affiliation:

1. Stanford Immune Behavioral Health Clinic and Research Program, Stanford University and Stanford Children's Health, Stanford, California, USA.
2. Division of Allergy, Immunology, and Rheumatology, Department of Pediatrics, Stanford University School of Medicine, Palo Alto, California, USA.

Address: 700 Welch Rd Suite 301, Palo Alto, CA 94305

Telephone: 650-399-6888

Jaynelle Gao, MS (jaynelle@stanford.edu)

Affiliations:

1. Stanford Immune Behavioral Health Clinic and Research Program, Stanford University and Stanford Children's Health, Stanford, California, USA.
2. Division of Allergy, Immunology, and Rheumatology, Department of Pediatrics, Stanford University School of Medicine, Palo Alto, California, USA.
3. Keck School of Medicine of University of Southern California, Los Angeles, California, USA.

Kate Miles, BS (jkmiles@stanford.edu)

Affiliation:

1. Stanford Immune Behavioral Health Clinic and Research Program, Stanford University and Stanford Children's Health, Stanford, California, USA.
2. Division of Allergy, Immunology, and Rheumatology, Department of Pediatrics, Stanford University School of Medicine, Palo Alto, California, USA.

Juliette Madan, MD, MS (juliette.c.madan@hitchcock.org)

Affiliation:

Department of Pediatrics & Psychiatry, Children's Hospital at Dartmouth, Dartmouth Health, Lebanon, New Hampshire, USA.

Mark Pasternack, MD (mpasternack@mgh.harvard.edu)

Affiliation:

Pediatric Infectious Disease Unit, Massachusetts General Hospital, Boston, Massachusetts, USA.

Ellen R. Wald, MD (erwald@wisc.edu)

Affiliation:

University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.

Samuel H. Gunther, PhD, MPH (shgunthr@stanford.edu)* (Corresponding Author)

Affiliation:

1. Stanford Immune Behavioral Health Clinic and Research Program, Stanford University and Stanford Children's Health, Stanford, California, USA.

2. Division of Allergy, Immunology, and Rheumatology, Department of Pediatrics, Stanford University School of Medicine, Palo Alto, California, USA.

Jennifer Frankovich, MD, MS (Frankovich_admin@stanford.edu)* (Corresponding Author)

Affiliations:

1. Stanford Immune Behavioral Health Clinic and Research Program, Stanford University and Stanford Children's Health, Stanford, California, USA.
2. Division of Allergy, Immunology, and Rheumatology, Department of Pediatrics, Stanford University School of Medicine, Palo Alto, California, USA.

* shared last author

Abstract

Background

Group A streptococcus (GAS) infections have been associated with neuropsychiatric disorders in epidemiologic studies and animal models, but data in US health care populations are limited. GAS is also associated with autoimmune sequelae, including acute rheumatic fever (ARF)/Sydenham chorea (SC), poststreptococcal reactive arthritis (PSRA), poststreptococcal glomerulonephritis (PSGN), and guttate psoriasis (GP). Epstein-Barr virus (EBV) has been linked to systemic lupus erythematosus (SLE) and multiple sclerosis (MS) and the complexity of these associations parallels that of GAS-associated conditions, providing a useful comparison.

Objectives

1) Assess the association between a positive GAS test and incident neuropsychiatric diagnoses within 1 year in a large US health care database. 2) Assess the validity of the same database in detecting well-established disease associations while avoiding false associations.

Design, Setting, Participants

Retrospective cohort study using TriNetX data from US health care organizations. Patients with positive or negative tests were propensity score–matched (GAS cohort n=178,301; EBV cohort n=64,854). Patients with documented neuropsychiatric diagnoses prior to testing were excluded. To approximate a primary care population, inclusion required at least one well-visit.

Exposures

Positive vs negative GAS test; positive vs negative EBV test (separate cohorts).

Main Outcomes and Validations

Main outcome: incident neuropsychiatric diagnoses within 1 year of GAS testing. Positive control outcomes: ARF/SC, PSRA, PSGN, and GP (for GAS cohort); SLE and MS (for EBV cohort). Negative control outcomes: conditions without known association with GAS.

Results

After matching, a positive GAS test was associated with attention-deficit/hyperactivity disorder (ADHD) (RR: 1.09; 95% CI: 1.03–1.15). Among established poststreptococcal conditions, only GP was associated with prior GAS (RR: 1.75; 95% CI: 1.06–2.89). Case counts were insufficient to evaluate ARF/SC, PSRA, and PSGN. Negative control outcomes showed no association. In the EBV cohort, no association was observed with SLE, and MS showed a decreased risk.

Conclusions and Relevance

A positive GAS test was associated with ADHD but not with other neuropsychiatric disorders. The database detected poststreptococcal GP but did not identify most established postinfectious autoimmune associations, likely reflecting rarity, heterogeneity, and diagnostic complexity. These findings begin to describe the range of real-world health care databases to evaluate postinfectious neuropsychiatric risk.

Introduction

Streptococcus pyogenes (group A streptococcus [GAS]) is a highly contagious pathogen that causes a spectrum of clinical disease, ranging from common superficial infections (*e.g.*, impetigo, perianal streptococcal dermatitis, streptococcal vaginitis, and pharyngitis)[1,2] to uncommon invasive infections (pneumonia, necrotizing fasciitis, toxic shock syndrome)[3–6]. Rarely, GAS can trigger autoimmune sequelae which can result in inflammation of the kidney, heart, joints, skin, and brain (basal ganglia). These diagnoses include acute rheumatic fever (ARF)[1,7–10]/Sydenham chorea (SC)[8,11–13], poststreptococcal arthritis (PSRA)[14–16], poststreptococcal glomerulonephritis (PSGN)[1,17–20], guttate psoriasis (GP)[21–25], and potentially other neurological sequelae[26(p201),27–34].

While both epidemiological[35–39] and animal studies[40–48] have suggested an association between GAS and neuropsychiatric diagnoses, establishing causality in clinical populations remains challenging because GAS infections are common, immune-mediated sequelae are rare, and symptoms often arise after the window for microbiologic detection[49]. While poststreptococcal associations with ARF, GP, PSRA, and SC are now widely accepted among clinicians, the relationship between GAS and neurobehavioral diagnoses is still being debated in the clinical arena.

One study supporting the association between GAS and neurobehavioral diagnoses is a school-based prospective cohort study by Murphy et al. In 693 schoolchildren, investigators obtained serial throat cultures and conducted concurrent direct observations of motor and behavioral symptoms. Positive GAS cultures were significantly associated with increased incidence of behavioral disturbances and choreiform movements[37]. The subset of children with GAS-

associated behavioral changes were suspected to have immunogenetic or neurologic susceptibility similar to ARF and SC.

Two other large, population-based studies using real-world data (RWD) have shown a link between streptococcal pharyngitis and neurobehavioral diagnoses. Orlovska et al. reported that patients in Denmark with streptococcal throat infections had an increased risk of developing all mental disorders, in particular obsessive-compulsive disorder (OCD) and tic disorders[38]. Similarly, Wang et al. reported increased risk of attention-deficit/hyperactivity disorder (ADHD) and tic disorders in patients within five years following GAS infections based on RWD from Taiwan[39].

Large-scale analyses of the association between GAS and neurobehavioral diagnoses using RWD are currently lacking in the US, however; potential tools include TriNetX, a HIPAA-compliant, federated network of health care organizations (HCOs) where data are updated in real time. The TriNetX US network primarily consists of academic medical center-based HCOs and research-focused non-academic centers with both hospital patients and outpatients, covering approximately 1.25 million patients[50–52].

The aim of this study was not to directly replicate findings from previous RWD studies, which were conducted in markedly different study populations and with different methods. Rather, we aimed to evaluate the utility of the TriNetX platform for examining associations between GAS infections and neuropsychiatric diagnoses in a US primary care patient population, with particular attention to its ability to detect—or appropriately avoid—associations across three categories of established ground truths: 1) well-established poststreptococcal diagnoses ARF[1,7–10]/SC[8,11–13], PSRA[14–16], PSGN[1,17–20], and GP[21–25]; 2) diagnoses with no known association with streptococcal infection (fracture of shaft of humerus and non-neoplastic nevi); 3) other well-

established postinfectious autoimmune diagnoses not related to GAS infection (Epstein–Barr virus (EBV)–associated diagnoses, *i.e.*, multiple sclerosis (MS)[53–58] and systemic lupus erythematosus (SLE)[59–64].

Methods

Data Source

The cohorts in this study were derived from 70 HCOs in the TriNetX US Collaborative Network[50–52]. TriNetX is accessible for academic use through collaboration agreements and uses ICD-10-CM (International Classification of Diseases, 10th Revision, Clinical Modification) codes to classify disease outcomes recorded by participating HCOs. Query codes for demographic categories and clinical outcomes (ICD-10-CM diagnoses) included in the analysis are shown in Appendix A.

Primary research question

Our primary aim was to assess the association between a positive GAS test and subsequent neuropsychiatric diagnoses within 1 year: "any mental, behavioral, and neurodevelopmental disorders" (referred to as "any mental disorders"); tic disorder; eating disorders; "anxiety, dissociative, stress-related, somatoform and other nonpsychotic mental disorders" (referred to as "anxiety disorders" and including OCD); OCD alone (separate from the other anxiety disorders); and ADHD[26–34].

Cohort construction

Positive/negative GAS cohorts: The cohort used to study poststreptococcal conditions included patients aged 5 to 18 years with a documented GAS laboratory test (Appendix A). Exclusion

criteria included pervasive developmental disorders, any psychiatric diagnosis prior to the GAS test, and absence of at least one encounter with a participating HCO coded as a "general examination without complaint, suspected, or reported diagnosis" (hereafter referred to as "well-visit"). The index event was defined as the GAS test among patients without prior psychiatric history who had at least one well-visit encounter. The positive GAS cohort included patients with a positive test result (n=178,301), and the negative cohort included patients with a negative test result (n=411,053).

Positive/negative EBV cohorts: The cohort used to study post–EBV conditions included patients with a documented EBV laboratory test (Appendix A). No age restriction was applied. Exclusion criteria included absence of at least one well-visit. The index event was defined as the EBV test among patients with at least one well-visit encounter. The positive EBV cohort included patients with a positive test result (n=70,217), and the negative EBV cohort included patients with a negative test result (n=86,909). No minimum follow-up time was imposed because MS and SLE can be diagnosed across a broad age range[65,66].

Statistical analysis

TriNetX uses built-in "advanced analytics" packages for statistical analysis. In our study, this involved applying a logit model using selected covariates (age at index, known sex, known ethnicities, known races) to create propensity scores for each patient. To eliminate potential bias that may occur with matching unknown demographics (*e.g.*, unknown race or unknown ethnicity), we required patients in our cohorts to have a known race or ethnicity. We also excluded patients with unknown sex and "other" race (*i.e.*, not White/Black/Asian/American Indian/Pacific Islander, or multiracial), as these categories are not able to be used in matched analyses.

TriNetX's built-in greedy nearest neighbor matching algorithm then paired patients between the defined cohorts. After matching, our GAS cohorts included 178,301 patients and our EBV cohorts included 64,854 patients. Finally, TriNetX constructed risk ratios (RRs) and 95% confidence intervals (CIs) by comparing outcomes between the matched sets of patients. An alpha level of 0.05 was used as the cutoff for statistical significance.

Assessing ability of TriNetX to detect ground truths

Ground Truth 1: Does TriNetX detect a well-established association between GAS and poststreptococcal inflammatory conditions?

To evaluate TriNetX's ability to detect established positive associations with poststreptococcal conditions, we selected the most well-established poststreptococcal diagnoses with corresponding ICD-10-CM codes. These include ARF[1,7–10]/SC[8,11–13], PSRA (coded as "Other streptococcal arthritis and polyarthritis" or "Other streptococcal polyarthritis")[14–16], PSGN[1,17–20], and GP[21–25].

Ground Truth 2: Does TriNetX detect associations between GAS and conditions presumed to be unrelated to GAS?

To evaluate TriNetX's ability to avoid false positives, we selected two diagnoses that should have no relationship with GAS: fracture of shaft of humerus, and non-neoplastic nevus.

Ground Truth 3: Does TriNetX detect associations between infections established to be associated with complex immunologic conditions?

To further evaluate TriNetX's ability to detect established positive associations using a different infection, we chose to study the association between EBV and two complex immunologic

conditions (MS and SLE). These conditions were selected because EBV has a well-established association with and MS[53–58] and SLE[59–64].

Assessing reliability of TriNetX

Analyses were conducted 5 times over the course of 3 months, and results fluctuated. This may have been due to participating TriNetX HCOs being variably offline (*e.g.*, during system maintenance), thereby affecting patient record availability. Final analyses and reported results were generated on December 17, 2025.

Results

GAS and neurobehavioral disorders

All results are shown in Table 1. Before matching, TriNetX showed positive associations between prior GAS and "any mental, behavioral, and neurodevelopmental disorders", tic disorder, OCD alone, and ADHD, with ADHD showing the strongest association (RR: 1.31; 95% CI: 1.25, 1.38). TriNetX did not detect an association between prior GAS and anxiety disorders and detected an inverse association between prior GAS and eating disorders (0.64; 0.49, 0.84). After matching, the only detected positive association was between prior GAS and ADHD (1.09; 1.03, 1.15), notably weaker than pre-matched results. Interestingly, findings for ADHD remained consistent thought multiple iterations of the analysis, despite the fluctuation in analytic results mentioned above.

GAS and ground truths

Positive ground truths: Findings for most ground truth hypotheses were also consistent throughout multiple iterations of the analysis. Before matching, TriNetX detected a positive

association between prior GAS and ARF and GP, which is consistent with established research[1,7–10,21–25]. However, TriNetX did not detect the well-established association between prior GAS and PSGN[1,17–20]. After matching, TriNetX could not detect these associations with the exception GP[21–25] (1.75; 1.06, 2.89). Insufficient patient counts did not allow for: 1) pre- and postmatching analysis of PSRA and SC; and 2) postmatching analyses for ARF and PSGN.

Negative ground truths: As expected, TriNetX did not detect an association between prior GAS and non-neoplastic nevus. Unexpectedly, it detected a positive association between GAS and fracture of shaft of humerus prior to matching (1.33; 1.08, 1.63), likely due to a confounding factor as the two are assumed to be unrelated. After matching, TriNetX did not detect an association between prior GAS and either condition.

Epstein-Barr virus and ground truths

Before and after matching, TriNetX detected an inverse association between prior EBV and MS (pre-matching: 0.75; 0.61, 0.92; postmatching: 0.72; 0.58, 0.90) and did not detect an association between prior EBV and SLE. These results were both unexpected, given the established associations between EBV infection, MS[53–58] and SLE[59–64].

Discussion

Summary of findings

This study assessed the capacity of the TriNetX data-sharing and analytics platform to examine associations between GAS infection and incident neuropsychiatric diagnoses within 1 year in a large US cohort. A positive GAS test result was associated with a modestly increased risk of ADHD. No associations were observed between GAS infection and most other mental health

disorders. Although an association with GP was identified, the platform did not reliably detect associations with well-established poststreptococcal sequelae (ARF[1,7–10]/SC[8,11–13], PSRA[14–16], PSGN[1,17–20]). Indeed, psychiatric symptoms have long been recognized to be a feature of SC, an established poststreptococcal condition with "failure of attention" as a commonly described symptom[1,8,11–13]. While this finding is not unexpected, as the study was not designed to directly replicate the results of prior investigations, a brief review of literature related to the role of GAS infections in neurobehavioral disorders suggests that TriNetX may simply have failed to detect existing associations.

GAS connection to neuropsychiatric symptoms

Neuropsychiatric symptoms described as potentially poststreptococcal in nature include: emotional lability[67], OCD, anxiety, ADHD, and occasionally psychosis[68,69]. Additionally, psychiatric symptoms have been described in patients with ARF who do not have chorea[70,71]. Animal models have elucidated biological mechanisms underlying the connection between GAS infection and neurobehavioral symptoms and include brain homing Th17 cells, disruption of the blood brain barrier, and autoantibodies which target dopamine receptors and cholinergic interneurons in the basal ganglia[40–48].

Based on these findings and the general understanding that ARF/SC patients have prominent psychiatric symptoms[72], epidemiological studies in diverse global populations have been pursued to investigate this association more broadly. In the US, Murphy et al. conducted blinded behavioral assessments and found that disruptive behaviors (*e.g.*, hair-pulling, excessive touching, swaying, and grimacing) and choreiform movements were associated with repeated positive GAS cultures[37]. In Europe, Orlovska et al. reported that, among 1,067,743 children in

the Danish National Health Service Register, a streptococcal test coupled with a prescription for an antibiotic was correlated with increased risk of any mental disorder, but especially OCD and tic disorders, compared to children without a positive test. The risk of any mental disorder and OCD was also found to be more elevated after a streptococcal throat infection than after a non-streptococcal infection, though children with non-streptococcal infections also had an increased risk of any mental disorder[38]. In Asia, Wang et al. investigated ICD-9-CM codes in a subset of the Taiwanese National Health Insurance Research Database and followed patients longitudinally. They found that inpatient treatment of streptococcal infections (scarlet fever and pneumonia) was associated with increased risk of mental disorders and ADHD with a peak occurrence 5 years after the inpatient treatment of the streptococcal infection. Outpatient detection of GAS infections was significantly associated with increased risk of ADHD and tic disorders in children with at least two infections, while patients with low frequency of clinic visits did not experience increased risk[39].

Limitations of TriNetX to study postinfectious conditions

The TriNetX database was not specifically designed to query postinfectious neurobehavioral disorders, and its inability to detect some expected associations between GAS/EBV and established postinfectious conditions raises the question of whether it is suitable for studying such relatively rare and complex outcomes, especially in close proximity (within 1 year) of the triggering infection. As many complex neuropsychiatric conditions have delayed diagnosis[39,73], this timeframe may have limited the ability to detect associations that could emerge with longer follow-up. While the sheer number of patient records provided by the TriNetX platform is impressive, obtaining accurate results is still dependent on several factors, including precise diagnostic coding, minimization of potential sources of bias, and robust statistical procedures.

Differences in case ascertainment may explain some of this dissonance. ADHD and GP are relatively common diagnoses that are readily recognized in primary care settings, whereas many poststreptococcal autoimmune conditions are rare, clinically heterogeneous, and more challenging to diagnose, especially since it is common for psychiatrists to work outside of the settings of HCOs represented in the TriNetX network. Case identification is further complicated by limitations in diagnostic coding. Beyond SC, there are no specific ICD-10 codes for poststreptococcal neuropsychiatric syndromes, including patients with ARF who present without chorea but experience emotional lability or other psychiatric manifestations[67,70,71]. Hence, the ICD codes used for our analyses (ICD-10-CM:F01-F99) represent broad diagnoses and varying pathogenic mechanisms, within which there may reside a rare subset which reflects poststreptococcal mechanisms. Reliable detection of uncommon and variably coded conditions may require larger, more population-based longitudinal registries than TriNetX is able to provide.

The specific context of our study—the US—also merits comment. The US modified ICD-10 into ICD-10-CM to create a granular set of codes for its complex, multi-payer insurance system[74,75]. This heterogeneity potentially results in systemic differences in training, validation, and recordkeeping, increasing the likelihood of recorded diagnoses being influenced by non-medical factors, and biasing the analysis of rare, diffuse conditions[51,76–81]. In particular, since TriNetX's HCOs are primarily academic settings and non-academic research settings[52], likely covering mostly insured and acute cases[51], referral bias from patients skewing towards end stages of disease, higher disease severity, and higher socioeconomic status may have been introduced.

We attempted to counteract this by setting the requirement that patients had at least one well-visit (ICD-10-CM:Z00), as it was assumed that this would be the patient's destination for regular

check-ups. However, factoring this into the analysis returned insufficient patient records for several outcomes. Likewise, no results were returned when a time-constraint was added or when two or more well-visits were required. This suggests a limited ability of TriNetX to address bias using its built-in functions, as opposed to databases that allow users to input their own analytical code for customized statistical analysis.

Future directions

The association between GAS and neuropsychiatric conditions remains an important area of focus, for researchers, clinicians, and parents of affected patients alike. Future epidemiologic investigations of streptococcal-associated neuropsychiatric disorders should incorporate robust methods such as prospective, direct observational designs to ensure uniformity and rigor in GAS testing (*e.g.*, standardized throat-swab collection protocols), as well as in neurologic and behavioral assessments. Platforms like TriNetX will have the potential to become reliable tools for RWD analyses in the US with expanded HCO representation, refined classification criteria for complex postinfectious conditions, more specific ICD-10 codes, and rigorous clinician training in ICD-10-CM coding[51,76,77,79–85].

Conclusions

Given a sufficiently large cohort, TriNetX was able to detect preceding GAS infections associated with a well-established, easily diagnosed poststreptococcal condition–GP–the most common poststreptococcal inflammatory disorder[21–25]. It also identified an association with ADHD, one of the most common neuropsychiatric disorders[86], which is consistently observed in Sydenham chorea[68,72]. TriNetX appears resistant to false-positive findings based on our parameters, as it did not detect associations between GAS and unrelated conditions. However, it

failed to identify associations with other well-established poststreptococcal autoimmune conditions, potentially due to their rarity, and did not find links between positive GAS tests and broader psychiatric categories—including “any mental disorder,” OCD, tic disorders, eating disorders, or anxiety disorders—after matching.

References

1. Cunningham Madeleine W. Pathogenesis of Group A Streptococcal Infections. *Clin Microbiol Rev*. 2000;13(3):470-511. doi:10.1128/cmr.13.3.470
2. Serban ED. Perianal infectious dermatitis: An underdiagnosed, unremitting and stubborn condition. *World J Clin Pediatr*. 2018;7(4):89-104. doi:10.5409/wjcp.v7.i4.89
3. Jaquiery A, Stylianopoulos A, Hogg G, Grover S. Vulvovaginitis: clinical features, aetiology, and microbiology of the genital tract. *Arch Dis Child*. 1999;81(1):64. doi:10.1136/adc.81.1.64
4. Mustafa Z, Ghaffari M. Diagnostic Methods, Clinical Guidelines, and Antibiotic Treatment for Group A Streptococcal Pharyngitis: A Narrative Review. *Front Cell Infect Microbiol*. 2020;Volume 10-2020. https://www.frontiersin.org/journals/cellular-and-infection-microbiology/articles/10.3389/fcimb.2020.563627
5. Stevens D. Severe Group A Streptococcal Infections. Published online 10 2016. https://pubmed.ncbi.nlm.nih.gov/26866227/
6. Stevens D. Streptococcus pyogenes Impetigo, Erysipelas, and Cellulitis. Published online 8 2022. https://pubmed.ncbi.nlm.nih.gov/36479753/
7. Chowdhury MS, Koziatek CA, Tristram D, Rajnik M. Acute Rheumatic Fever. In: *StatPearls*. StatPearls Publishing; 2025. http://www.ncbi.nlm.nih.gov/books/NBK594238/
8. Cunningham MW. PostStreptococcal Autoimmune Sequelae: Rheumatic Fever and Beyond. In: Ferretti JJ, Stevens DL, Fischetti VA, eds. *Streptococcus Pyogenes: Basic Biology to Clinical Manifestations*. University of Oklahoma Health Sciences Center; 2016. http://www.ncbi.nlm.nih.gov/books/NBK333434/
9. Dajani AS, Ayoub E, Bierman FZ, et al. Guidelines for the Diagnosis of Rheumatic Fever: Jones Criteria, 1992 Update. *JAMA*. 1992;268(15):2069-2073. doi:10.1001/jama.1992.03490150121036
10. Gewitz MH, Baltimore RS, Tani LY, et al. Revision of the Jones Criteria for the Diagnosis of Acute Rheumatic Fever in the Era of Doppler Echocardiography. *Circulation*. 2015;131(20):1806-1818. doi:10.1161/CIR.0000000000000205
11. Beier K, Lui F, Pratt DP. Sydenham Chorea. In: *StatPearls*. StatPearls Publishing; 2025. http://www.ncbi.nlm.nih.gov/books/NBK430838/
12. Teixeira AL, Vasconcelos LP, Nunes M do CP, Singer H. Sydenham's chorea: from pathophysiology to therapeutics. *Expert Rev Neurother*. 2021;21(8):913-922. doi:10.1080/14737175.2021.1965883
13. Zomorrodi A, Wald ER. Sydenham's chorea in western Pennsylvania. *Pediatrics*. 2006;117(4):e675-9. doi:10.1542/peds.2005-1573
14. Arnold MH, Tyndall A. Poststreptococcal reactive arthritis. *Ann Rheum Dis*. 1989;48(8):686-688. doi:10.1136/ard.48.8.686
15. Bawazir Y, Towheed T, Anastassiades T. PostStreptococcal Reactive Arthritis. *Curr Rheumatol Rev*. 2020;16(1):2-8. doi:10.2174/1573397115666190808110337

16. Li EK. Rheumatic disorders associated with streptococcal infections. *Baillieres Best Pr Res Clin Rheumatol*. 2000;14(3):559-578. doi:10.1053/berh.2000.0093
17. Alhamoud MA, Salloot IZ, Mohiuddin SS, et al. A Comprehensive Review Study on Glomerulonephritis Associated With Poststreptococcal Infection. *Cureus*. 2021;13(12):e20212. doi:10.7759/cureus.20212
18. Blyth CC, Robertson PW, Rosenberg AR. Poststreptococcal glomerulonephritis in Sydney: A 16-year retrospective review. *J Paediatr Child Health*. 2007;43(6):446-450. doi:10.1111/j.1440-1754.2007.01109.x
19. Hunt EAK, Somers MJG. Infection-Related Glomerulonephritis. *Pediatr Clin North Am*. 2019;66(1):59-72. doi:10.1016/j.pcl.2018.08.005
20. Rammelkamp CH Jr, Weaver RS. ACUTE GLOMERULONEPHRITIS. THE SIGNIFICANCE OF THE VARIATIONS IN THE INCIDENCE OF THE DISEASE. *J Clin Invest*. 1953;32(4):345-358. doi:10.1172/JCI102745
21. BAKER BS, BOKTH S, POWLES A, et al. Group A streptococcal antigen□specific T lymphocytes in guttate psoriatic lesions. *Br J Dermatol*. 1993;128(5):493-499. doi:10.1111/j.1365-2133.1993.tb00224.x
22. Saleh D, Tanner LS. Guttate Psoriasis. In: *StatPearls*. StatPearls Publishing; 2025. http://www.ncbi.nlm.nih.gov/books/NBK482498/
23. Telfer NR, Chalmers RJ, Whale K, Colman G. The role of streptococcal infection in the initiation of guttate psoriasis. *Arch Dermatol*. 1992;128(1):39-42.
24. WHYTE HJ, BAUGHMAN RD. Acute Guttate Psoriasis and Streptococcal Infection. *Arch Dermatol*. 1964;89(3):350-356. doi:10.1001/archderm.1964.01590270036008
25. Zhao G, Feng X, Na A, et al. Acute Guttate Psoriasis Patients Have Positive Streptococcus Hemolyticus Throat Cultures and Elevated Antistreptococcal M6 Protein Titers. *J Dermatol*. 2005;32(2):91-96. doi:10.1111/j.1346-8138.2005.tb00723.x
26. Calaprice D. A Survey of Pediatric Acute-Onset Neuropsychiatric Syndrome Characteristics and Course. Published online 2017. doi:10.1089/cap.2016.0105
27. Cardona F, Orefici G. Group A streptococcal infections and tic disorders in an Italian pediatric population. *J Pediatr*. 2001;138(1):71-75. doi:10.1067/mpd.2001.110325
28. Frankovich J, Thienemann M, Pearlstein J, Crable A, Brown K, Chang K. Multidisciplinary Clinic Dedicated to Treating Youth with Pediatric Acute-Onset Neuropsychiatric Syndrome: Presenting Characteristics of the First 47 Consecutive Patients. *J Child Adolesc Psychopharmacol*. 2015;25(1):38-47. doi:10.1089/cap.2014.0081
29. Gamucci A, Uccella S, Sciarretta L, et al. PANDAS and PANS: Clinical, Neuropsychological, and Biological Characterization of a Monocentric Series of Patients and Proposal for a Diagnostic Protocol. *J Child Adolesc Psychopharmacol*. 2019;29(4):305-312. doi:10.1089/cap.2018.0087
30. Gromark C, Harris RA, Wickström R, et al. Establishing a Pediatric Acute-Onset Neuropsychiatric Syndrome Clinic: Baseline Clinical Features of the Pediatric Acute-Onset

Neuropsychiatric Syndrome Cohort at Karolinska Institutet. *J Child Adolesc Psychopharmacol*. 2019;29(8):625-633. doi:10.1089/cap.2018.0127
31. Murphy ML, Pichichero ME. Prospective Identification and Treatment of Children With Pediatric Autoimmune Neuropsychiatric Disorder Associated With Group A Streptococcal Infection (PANDAS). *Arch Pediatr Adolesc Med*. 2002;156(4):356-361. doi:10.1001/archpedi.156.4.356
32. Murphy TK, Patel PD, McGuire JF, et al. Characterization of the Pediatric Acute-Onset Neuropsychiatric Syndrome Phenotype. *J Child Adolesc Psychopharmacol*. 2015;25(1):14-25. doi:10.1089/cap.2014.0062
33. Spinello C, Laviola G, Macrì S. Pediatric Autoimmune Disorders Associated with Streptococcal Infections and Tourette's Syndrome in Preclinical Studies. *Front Neurosci*. 2016;Volume 10-2016. https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2016.00310
34. Toufexis MD, Hommer R, Gerardi DM, et al. Disordered Eating and Food Restrictions in Children with PANDAS/PANS. *J Child Adolesc Psychopharmacol*. 2015;25(1):48-56. doi:10.1089/cap.2014.0063
35. Leslie DL, Kozma L, Martin A, et al. Neuropsychiatric disorders associated with streptococcal infection: a case-control study among privately insured children. *J Am Acad Child Adolesc Psychiatry*. 2008;47(10):1166-1172. doi:10.1097/CHI.0b013e3181825a3d
36. Mell LK, Davis RL, Owens D. Association between streptococcal infection and obsessive-compulsive disorder, Tourette's syndrome, and tic disorder. *Pediatrics*. 2005;116(1):56-60. doi:10.1542/peds.2004-2058
37. Murphy TK, Snider LA, Mutch PJ, et al. Relationship of Movements and Behaviors to Group A Streptococcus Infections in Elementary School Children. *Biol Psychiatry*. 2007;61(3):279-284. doi:10.1016/j.biopsych.2006.08.031
38. Orlovska S, Vestergaard CH, Bech BH, Nordentoft M, Vestergaard M, Benros ME. Association of Streptococcal Throat Infection With Mental Disorders: Testing Key Aspects of the PANDAS Hypothesis in a Nationwide Study. *JAMA Psychiatry*. 2017;74(7):740-746. doi:10.1001/jamapsychiatry.2017.0995
39. Wang HC, Lau CI, Lin CC, Chang A, Kao CH. Group A Streptococcal Infections Are Associated With Increased Risk of Pediatric Neuropsychiatric Disorders: A Taiwanese Population-Based Cohort Study. *J Clin Psychiatry*. 2016;77(7):e848-54. doi:10.4088/JCP.14m09728
40. Brimberg L. Behavioral, pharmacological, and immunological abnormalities after streptococcal exposure: a novel rat model of Sydenham chorea and related neuropsychiatric disorders. Published online 25 2012. doi:10.1038/npp.2012.56
41. Cutforth T. CNS autoimmune disease after Streptococcus pyogenes infections: animal models, cellular mechanisms and genetic factors. Published online 2016. doi:10.2217/fnl.16.4
42. Dileepan T. Group A Streptococcus intranasal infection promotes CNS infiltration by streptococcal-specific Th17 cells. Published online 14 2015. doi:10.1172/JCI80792

43. Frick LR, Rapanelli M, Jindachomthong K, et al. Differential binding of antibodies in PANDAS patients to cholinergic interneurons in the striatum. *Brain Behav Immun*. 2017;69:304-311. doi:10.1016/j.bbi.2017.12.004
44. Lotan D, Benhar I, Alvarez K, et al. Behavioral and neural effects of intra-striatal infusion of anti-streptococcal antibodies in rats. *Brain Behav Immun*. 2014;38:249-262. doi:10.1016/j.bbi.2014.02.009
45. Yaddanapudi K, Hornig M, Serge R, et al. Passive transfer of streptococcus-induced antibodies reproduces behavioral disturbances in a mouse model of pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection. *Mol Psychiatry*. 2010;15(7):712-726. doi:10.1038/mp.2009.77
46. Lotan D, Cunningham M, Joel D. Antibiotic treatment attenuates behavioral and neurochemical changes induced by exposure of rats to group a streptococcal antigen. *PLoS One*. 2014;9(6):e101257. doi:10.1371/journal.pone.0101257
47. Cox C. Brain Human Monoclonal Autoantibody from Sydenham Chorea Targets Dopaminergic Neurons in Transgenic Mice and Signals Dopamine D2 Receptor: Implications in Human Disease. Published online 2013. doi:10.4049/jimmunol.1102592
48. Hoffman KL, Hornig M, Yaddanapudi K, Jabado O, Lipkin WI. A Murine Model for Neuropsychiatric Disorders Associated with Group A β-Hemolytic Streptococcal Infection. *J Neurosci*. 2004;24(7):1780. doi:10.1523/JNEUROSCI.0887-03.2004
49. Stollerman GH. Rheumatic Fever in the 21st Century. *Clin Infect Dis*. 2001;33(6):806-814. doi:10.1086/322665
50. Ludwig RJ, Anson M, Zirpel H, et al. A comprehensive review of methodologies and application to use the real-world data and analytics platform TriNetX. *Front Pharmacol*. 2025;Volume 16-2025. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1516126
51. Nassar M, Abosheaishaa H, Elfert K, et al. TriNetX and Real-World Evidence: A Critical Review of Its Strengths, Limitations, and Bias Considerations in Clinical Research. *Intern Med*. 2025;1(2):24-32. doi:10.71079/ASIDE.IM.03222516
52. Palchuk MB, London JW, Perez-Rey D, et al. A global federated real-world data and analytics platform for research. *JAMIA Open*. 2023;6(2):ooad035. doi:10.1093/jamiaopen/ooad035
53. Aloisi F, Giovannoni G, Salvetti M. Epstein-Barr virus as a cause of multiple sclerosis: opportunities for prevention and therapy. *Lancet Neurol*. 2023;22(4):338-349. doi:10.1016/S1474-4422(22)00471-9
54. Bjornevik K, Cortese M, Healy BC, et al. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. *Science*. 2022;375(6578):296-301. doi:10.1126/science.abj8222
55. Läderach F, Piteros I, Fennell É, et al. EBV induces CNS homing of B cells attracting inflammatory T cells. *Nature*. 2025;646(8083):171-179. doi:10.1038/s41586-025-09378-0

56. Lanz TV, Brewer RC, Ho PP, et al. Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM. *Nature*. 2022;603(7900):321-327. doi:10.1038/s41586-022-04432-7
57. Oksenberg JR, Baranzini SE, Sawcer S, Hauser SL. The genetics of multiple sclerosis: SNPs to pathways to pathogenesis. *Nat Rev Genet*. 2008;9(7):516-526. doi:10.1038/nrg2395
58. Soldan SS, Lieberman PM. Epstein–Barr virus and multiple sclerosis. *Nat Rev Microbiol*. 2023;21(1):51-64. doi:10.1038/s41579-022-00770-5
59. Draborg AH, Jacobsen S, Westergaard M, et al. Reduced response to Epstein-Barr virus antigens by T-cells in systemic lupus erythematosus patients. *Lupus Sci Med*. 2014;1(1):e000015. doi:10.1136/lupus-2014-000015
60. Hanlon P, Avenell A, Aucott L, Vickers MA. Systematic review and meta-analysis of the sero-epidemiological association between Epstein-Barr virus and systemic lupus erythematosus. *Arthritis Res Ther*. 2014;16(1):R3. doi:10.1186/ar4429
61. Jog NR, James JA. Epstein Barr Virus and Autoimmune Responses in Systemic Lupus Erythematosus. *Front Immunol*. 2021;Volume 11-2020. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2020.623944
62. Li ZX, Zeng S, Wu HX, Zhou Y. The risk of systemic lupus erythematosus associated with Epstein–Barr virus infection: a systematic review and meta-analysis. *Clin Exp Med*. 2019;19(1):23-36. doi:10.1007/s10238-018-0535-0
63. Moon UY, Park SJ, Oh ST, et al. Patients with systemic lupus erythematosus have abnormally elevated Epstein-Barr virus load in blood. *Arthritis Res Ther*. 2004;6(4):R295-302. doi:10.1186/ar1181
64. Younis S, Moutusy SI, Rasouli S, et al. Epstein-Barr virus reprograms autoreactive B cells as antigen-presenting cells in systemic lupus erythematosus. *Sci Transl Med*. 2025;17(824):eady0210. doi:10.1126/scitranslmed.ady0210
65. Merola J. Clinical Manifestations and Survival among Adults with Systemic Lupus Erythematosus according to Age at Diagnosis. Published online Summer 2015. doi:doi:%2010.1177/0961203314526291
66. Prosperini L, Lucchini M, Ruggieri S, et al. Shift of multiple sclerosis onset towards older age. *J Neurol Neurosurg Amp Psychiatry*. 2022;93(10):1137. doi:10.1136/jnnp-2022-329049
67. EBAUGH FG. NEUROPSYCHIATRIC ASPECTS OF CHOREA IN CHILDREN. *J Am Med Assoc*. 1926;87(14):1083-1088. doi:10.1001/jama.1926.02680140001001
68. Punukollu M, Mushet N, Linney M, Hennessy C, Morton M. Neuropsychiatric manifestations of Sydenham's chorea: a systematic review. *Dev Med Child Neurol*. 2015;58(1):16-28. doi:10.1111/dmcn.12786
69. Eyre M, Thomas T, Ferrarin E, et al. Treatments and Outcomes Among Patients with Sydenham Chorea: A Meta-Analysis. *JAMA Netw Open*. 2024;7(4):e246792. doi:10.1001/jamanetworkopen.2024.6792

70. Hounie AG, Pauls DL, Mercadante MT, et al. Obsessive-compulsive spectrum disorders in rheumatic fever with and without Sydenham's chorea. *J Clin Psychiatry*. 2004;65(7):994-999. doi:10.4088/jcp.v65n0717
71. Vasconcelos LPB, da Silva Bastos Vasconcelos MC, Di Flora FBME, et al. Neurological and Psychiatric Disorders in Patients with Rheumatic Heart Disease: Unveiling what is Beyond Cardiac Manifestations. *Glob Heart*. 2022;17(1):62. doi:10.5334/gh.1149
72. Mercadante Marcos T., Busatto Geraldo F., Lombroso Paul J., et al. The Psychiatric Symptoms of Rheumatic Fever. *Am J Psychiatry*. 2000;157:2036-2038. doi:10.1176/appi.ajp.157.12.2036
73. Wang PS, Berglund PA, Olfson M, Kessler RC. Delays in initial treatment contact after first onset of a mental disorder. *Health Serv Res*. 2004;39(2):393-415. doi:10.1111/j.1475-6773.2004.00234.x
74. Hirsch JA, Nicola G, McGinty G, et al. ICD-10: History and Context. *Am J Neuroradiol*. 2016;37(4):596. doi:10.3174/ajnr.A4696
75. Sanders T. The Road to ICD-10-CM/PCS Implementation: Forecasting the Transition for Providers, Payers, and Other Healthcare Organizations. Published online Spring 2012.
76. Burks K, Shields J, Evans J, Plumley J, Gerlach J, Flesher S. A systematic review of outpatient billing practices. *SAGE Open Med*. 2022;10:20503121221099021. doi:10.1177/20503121221099021
77. Horsky J, Drucker EA, Ramelson HZ. Accuracy and Completeness of Clinical Coding Using ICD-10 for Ambulatory Visits. *AMIA Annu Symp Proc*. 2018;2017:912-920.
78. Liebovitz DM, Fahrenbach J. COUNTERPOINT: Is ICD-10 Diagnosis Coding Important in the Era of Big Data? No. *CHEST*. 2018;153(5):1095-1098. doi:10.1016/j.chest.2018.01.034
79. Weiner MG. POINT: Is ICD-10 Diagnosis Coding Important in the Era of Big Data? Yes. *CHEST*. 2018;153(5):1093-1095. doi:10.1016/j.chest.2018.01.025
80. Weiner MG. Rebuttal From Dr Weiner. *CHEST*. 2018;153(5):1098-1099. doi:10.1016/j.chest.2018.01.027
81. Lin TL, Chen YJ, Wu CY. Choosing real-world data for clinical and epidemiological research: methodological lessons from NHIRD and TriNetX—A narrative review. *Ann Med*. 2026;58(1):2616549. doi:10.1080/07853890.2026.2616549
82. Surján G. Questions on validity of International Classification of Diseases-coded diagnoses. *Int J Med Inf*. 1999;54(2):77-95. doi:10.1016/s1386-5056(98)00171-3
83. Thigpen JL, Dillon C, Forster KB, et al. Validity of International Classification of Disease Codes to Identify Ischemic Stroke and Intracranial Hemorrhage Among Individuals With Associated Diagnosis of Atrial Fibrillation. *Circ Cardiovasc Qual Outcomes*. 2015;8(1):8-14. doi:10.1161/CIRCOUTCOMES.113.000371
84. Tu N, Henderson M, Sundararajan M, Salas M. Discrepancies in ICD-9/ICD-10-based codes used to identify three common diseases in cancer patients in real-world settings and their implications for disease classification in breast cancer patients and patients without cancer: a

literature review and descriptive study. *Front Oncol*. 2023;13:1016389. doi:10.3389/fonc.2023.1016389
85. Wong J, Abrahamowicz M, Buckeridge DL, Tamblyn R. Assessing the accuracy of using diagnostic codes from administrative data to infer antidepressant treatment indications: a validation study. *Pharmacoepidemiol Drug Saf*. 2018;27(10):1101-1111. doi:10.1002/pds.4436
86. Merikangas KR, He J ping, Burstein M, et al. Lifetime Prevalence of Mental Disorders in U.S. Adolescents: Results from the National Comorbidity Survey Replication–Adolescent Supplement (NCS-A). *J Am Acad Child Adolesc Psychiatry*. 2010;49(10):980-989. doi:10.1016/j.jaac.2010.05.017